PEANUT ALLERGY

This early-stage trial is testing whether a microneedle patch called MOON101, which delivers tiny amounts of peanut protein into the skin, is safe for people with peanut allergies. The study will enroll 40 participants, including adults, teenagers, and children. Each person will …

This Phase 2 trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy (OIT) helps people with peanut allergy tolerate more peanut without symptoms. 62 participants aged 12 to 55 will first receive tezepelumab or placebo alone, then both groups undergo…

This study tests a new injection called UKK-0018 for people with peanut allergies. The goal is to train the immune system to handle peanut exposure without a severe reaction. The trial involves 40 adults aged 18-55 and will first check safety, then see if it helps increase the am…

This study tests modified oral immunotherapy (OIT) protocols for peanut, milk, and egg allergies in 360 participants. The goal is to see if using lower doses or processed allergens can reduce allergic reactions during treatment while still helping people become desensitized to th…

This study tests a new daily oral treatment called ENP-501 for peanut allergy. It involves 68 healthy volunteers and people with a known peanut allergy. The treatment is given under the tongue daily for up to 52 weeks to see if it is safe and helps people tolerate peanut protein …

This program provides continued access to the Viaskin Peanut skin patch for children aged 2 and older with peanut allergy who previously completed a DBV712 study. The patch delivers a small amount of peanut protein through the skin each day to help desensitize the immune system. …